BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...

today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in ...

today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in ...

to respond favorably to olutasidenib, although the sample sizes are small for some co-mutations. Presenter: Andrew H. Wei, MBBS, Ph.D. In a separate cohort (n=18) of the Phase 2 trial ...

The poster presentation, based on a post-hoc analysis ... but after 96 weeks it was similar. For example, qFibrosis® analysis of Week 96 biopsy samples from 50mg EFX patients (N=26) revealed ...

NEWTON, Mass., May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract ...

The poster presentation, based on a post-hoc analysis of the 96-week ... but after 96 weeks it was similar. For example, qFibrosis® analysis of Week 96 biopsy samples from 50mg EFX patients (N=26) ...

Neonates with severe or moderate vs. mild bronchopulmonary dysplasia had a larger ciliary beat bended angle and a smaller ...

Immunic to Participate in Investor, Scientific and Industry Conferences in June ...